PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

22264 U.S. PTO 10/681690

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of Inventor(s): Vincent Chau

For: HUMAN PROTEINS RESPONSIBLE FOR NEDDS ACTIVATION AND CONJUGATION

1.	Type	of	Application
----	------	----	-------------

	w application is for a(n) () Original (nonprovisional) () Design	
	() Plant () Divisional.	
	(X) Continuation. Continuation-in-part (C-I-P).	
		C.F.R. SECTIONS 1.8(a) and 1.10*
I hereby	certify that, on the date shown below, this corresponder	ence is being:
æ	MAI deposited with the United States Postal Service in an Commissioner for Patents, P.O. Box 1450, Alexandria 37 C.F.R. SECTION 1.8(a)	envelope addressed to the Mail Stop Patent Application, ia, VA 22313-1450. 37 C.F.R. SECTION 1.10*
	with sufficient postage as first class mail.	as "Express Mail Post Office to Addressee" Mailing Label No. <u>EV322209726US</u>
	TRANS transmitted by facsimile to the Patent and Trademark	SMISSION Office. Signature
Date:_(October 8, 2003	Sean Hunziker (type or print name of person certifying)

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).

"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

- Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121) 2.
 - The new application being transmitted claims the benefit of prior U.S Application Serial (X) No. 09/216,430 filed December 18, 1998, which is a continuation-in-part of prior U.S. Provisional Application Serial No. 60/068,209 filed December 19, 1997, and a continuation-in-part of U.S. Provisional Application Serial No. 60/096,525 filed August 12, 1998.

3.	Maintenance (of	Copendency o	f	Prior	A	pplication
----	---------------	----	--------------	---	-------	---	------------

	·
3.	Maintenance of Copendency of Prior Application
	A. [] Extension of time in prior application filed concurrently by facsimile a copy of which is enclosed.
	B. () Conditional Petition for Extension of Time in Prior Application
	(lata this item it nrovious IIPM NOL (III) ILCUVIE)
	(complete this item, y previous term not application application. () A conditional petition for extension of time is being filed in the pending prior application. () A copy of the conditional petition filed in the prior application is attached.
4.	Abandonment of Prior Application (if applicable) [] Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.
	Notification in Parent Application of This Filing
	A notification of this continuation is being fried in the parent application from which
	application claims priority under 35 U.S.C. Section 120.
5.	Papers Enclosed Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application
	57 Pages of Specification, including
	48 Pages of Description
	8 Pages of Claims
	1 Page of Abstract
	9 Sheet of Drawings (Figure(s) 1-8)
	The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).
	[X] Formal [] Informal
	() 1111/11111111

	Addit	ional Papers Enclosed
	(X) (X) (X) (X)	Information Disclosure Statement (37 C.F.R. Section 1.98)(2 pages) Form PTO-1449 (PTO/SB/08A and 08B)(5 pages) Citations Declaration of Biological Deposit 31 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823) and 4 pages of Submission of "Sequence Listing," Computer Readable Copy, and/or Amendment Pertaining Thereto for Biotechnology Invention Containing Nucleotide and/or Amino Acid Sequence (37 CFR Section 1.821(f)) Authorization of Attorney(s) to Accept and Follow Instructions from Representative Special Comments Other: Preliminary Amendment (8 pages)
7.	• •	aration or Oath (including power of attorney)
	(X)	(3 pages) Copy of the executed Declaration and Power of Attorney document filed in prior U.S. Application Serial No. 09/216,430, filed December 18, 1998.
	()	Not Enclosed.
8.	Assi	gnment
	(X)	(19 pages) Copy of the recorded Assignment of the invention from the Inventor, Vincent Chau to Proscript, Inc. (7 pages); copy of the recorded Merger document from Proscript, Inc. to Leukosite, Inc. (7 pages); and copy of the recorded Merger document from Leukosite, Inc. to Millennium Pharmaceuticals, Inc. (5 pages); all filed in prior U.S. Application Serial No. 09/216,430, filed December 18, 1998, a copy of which
		[X] is enclosed. [) will follow.

- 9. Fee Calculation (37 C.F.R. Section 1.16)
 - A. (x) Regular application

		CLAIMS AS F	ILED		
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$770.00
Total Claims (37 C.F.R. Section 1.16(c))	27	- 20 =	7	\$18.00	\$126.00
Independent Claims (37 C.F.R. Section 1.16(b))	5	- 3 =	2	\$86.00	\$172.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	0	\$280.00			\$0.00

Filing Fee Calculation

\$1068.00

(x)	Amendment canceling extra claims is enclosed.
()	Amendment deleting multiple-dependencies is enclosed
ίí	Fee for extra claims is not being paid at this time.

... · ...

10.	Method () (X)	Check in the amount of \$ Charge Account No. 501668 in the amount of A duplicate of this transmittal is attached.
11.	Author (X)	ization to Charge Additional Fees The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 501668.
		 [X] 37 C.F.R. Section 1.16(a), (f) or (g) (filing fees) [X] 37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims) [Y] 37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application) [X] 37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a). [X] 37 C.F.R. Section 1.17 (application processing fees) [Y] 37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))
12.	Instruction [x]	Credit Account No. 501668. Refund
13.		spondence Address all future correspondence to: Customer Number 30405 OR Intellectual Property Department MILLENNIUM PHARMACEUTICALS, INC. 75 Sidney Street Cambridge, MA 02139
Octob	er 8, 200	
		Kerri Pollard Schray Registration No. 47,066 75 Sidney Sreet Cambridge, MA 02139 Telephone – (617) 551-3676 Facsimile – (617) 551-8820
(X)	Stater	nent Where No Further Pages Added
	(X)	This transmittal ends with this page.

PATENT

Practitioner's Docket No. MPI97-057P1RCP1CN1M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Vincent Chau

Application No.:

Filed:

Herewith

Examiner:

Group No.:

N/A

N/A

For:

HUMAN PROTEINS RESPONSIBLE FOR NEDDS ACTIVATION AND

CONJUGATION

Mail Stop Patent Application **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

1. This submission accompanies the new application being filed concurrently herewith

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I	, Kerri Pollard Schray		
	(type or print name	of person sig	gning below)
s	state the following:		
	CERTIFICATION UNDER 3	C.F.R. SECT	FIONS 1.8(a) and 1.10*
I here	by certify that, on the date shown below, this correspon	dence is being:	:
		AILING	
×	deposited with the United States Postal Service in a	ın envelope ado	dressed to Mail Stop Patent Application,
_	Commissioner for Patents, P.O. Box 1450, Alexand	Iria, VA 2231	3-1450.
	37 C.F.R. SECTION 1.8(a)		37 C.F.R. SECTION 1.10*
	with sufficient postage as first class mail.	×	as "Express Mail Post Office to Addressee" Mailing Label No. <u>EV322209726US</u>
	TRA	NSMISSION	<u>.</u>
	transmitted by facsimile to the Patent and Tradema	rk Office.	Sem Short
		Signa	ature
Date	: October 8, 2003		
		Sean	Hunziker

(type or print name of person certifying) *WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442. (Page 1 of 4)

ITEMS BEING SUBMITTED

	3.	Submitted	herewith	is/ar	e:
--	----	-----------	----------	-------	----

- A. [X] "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B. () An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. [] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. [X] Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:	Vincent Chau			
Application No.:	09/216,430	Group No.:	1652	
Filed:	December 18, 1998	Examiner:	Frona, Christian L.	
For:	HUMAN PROTEINS RESPONSIBLE FOR NEDDS ACTIVATION AND			
	CONJUGATION			

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form	"Sequence Identifier"
(other application)	(this application)

E.	[X]	A statement	that the	content	of each	"Sequence	Listing"	submitted	and	each	computer
		readable cop	y are the	same, as i	required	in 37 C.F.R.	Section	1.821(f).			

()	Because the statement is not made by a person registered	d to	practice	before	the	Office,
	the Statement is verified as required in 37 C.F.R. Section	1.8	21(b).			

4.

	F. ()	1.821(g), a statemer [] Because the sta	ission is made in fulfilling the requirent that the submission includes no new mate tement is not made by a person registered verified, as required in 37 C.F.R. Section	ter. I to practice l		
		AND CO	TEMENT THAT "SEQUENCE LISTIN MPUTER READABLE COPY ARE TH PAPERS SUBMITTED INCLUDES NO	E SAME	ΓER	
4.	I hereb	y state:				
	A. [X]		able form submitted in this application, incapplicant's other application, is the same as tete.			
	B. [X] All papers accompanying this submission, or for which a request for transfer from applicant other application, introduce no new matter.					
			EXTENSION OF TERM			
5.	The pro	ceedings herein are fo	or a patent application and the provisions of	37 C.F.R. Sec	tion 1.136 apply.	
(a) [] Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F. Section 1.17(a)(1)-(4)) for the total number of months checked below:						
	Ex	tension	Fee for other than		Fee for	
	<u>(m</u>	onths)	small entity		small entity	
	ر)	one month	\$ 110.00		\$ 55.00	
		two months	\$ 390.00		\$ 195.00	
		three months	\$ 890.00		\$ 445.00	
	()	four months	\$1,390.00		\$ 695.00	
				Fee	\$0.00	
If	an additi	onal extension of time	e is required, please consider this a petition	therefor.		
		() An extension for \$0.00 now requested.	or months has already been secured is deducted from the total fee due for the	, and the fee p total months o	aid therefor of of extension	

OR

(b) [X] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

	PEE PAYMENI			
6. [] Attached is a check in the sum of \$_	·			
() Charge Account No. <u>501668</u> the A duplicate of this transmittal is attack	· · · · · · · · · · · · · · · · · · ·			
F	EE DEFICIENCY			
8. [X] If any additional extension and/or fee is required, charge Account No. 501668.				
October 8, 2003	MILLENNIUM PHARMACEUTICALS, INC.			
	By Kall Sey			
	Kerri Pollard Schray			
	Attorney/Agent for Applicant			
	Registration No. 47,066			
	75 Sidney Street			
	Cambridge, MA 02139			
	Telephone – (617) 551-3676			
	Facsimile – (617) 551-8820			